-
公开(公告)号：EP1957464A1
公开(公告)日：2008-08-20
申请号：EP06817391.3
申请日：2006-10-27
Applicant: ABBOTT LABORATORIES
Inventor： GOMTSYAN, Arthur, R. , BAYBURT, Erol, K. , KOENIG, John, R. , MARSH, Kennan, C. , SCHMIDT, Robert, G., Jr. , LEE, Chih-Hung , WANG, Weili , DAANEN, Jerome, F. , BROWN, Brian, S.
IPC: C07D231/56 , C07D407/12 , A61K31/416 , A61P13/00
CPC classification number: C07D405/12 , C07D231/56 , C07D403/12 , C07F9/65038
Abstract: Compounds of formula (I), wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.
-
32.发明公开
公开(公告)号：EP1885704A2
公开(公告)日：2008-02-13
申请号：EP06759574.4
申请日：2006-05-10
Applicant: ABBOTT LABORATORIES
Inventor： GOMTSYAN, Arthur , PERNER, Richard , KOENIG, John , HSU, Margaret Chi-Ping , FERNANDO, Dilini , LEE, Chih-Hung
IPC: C07D263/48 , A61K31/421 , A61P29/00
CPC classification number: C07D263/48
Abstract: The present invention is directed to compounds of formula (I) (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
-
公开(公告)号：EP1646621A2
公开(公告)日：2006-04-19
申请号：EP04777733.9
申请日：2004-07-09
Applicant: ABBOTT LABORATORIES
Inventor： ZHENG, Guo Zhu , BROWN, Brian, S. , TURNER, Sean, C. , WHITE, Tammie, K. , SCHMIDT, Robert, G. , KOENIG, John, R. , LEE, Chih-Hung
IPC: C07D401/04 , C07D401/12 , C07D487/08 , A61K31/4525 , A61K31/4995 , A61P25/04
CPC classification number: C07D401/04 , C07D487/08
Abstract: The present invention relates to compounds of formula (I-VII) (I), or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7and R8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.
-
34.发明授权TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS 有权（1S）-1,2,3,4-四氢-1-萘酰基]苯甲酰胺类化合物，其抑制含P2X3和P2X2 / 3的受体
公开(公告)号：EP1392643B1
公开(公告)日：2005-09-14
申请号：EP02739257.0
申请日：2002-05-14
Applicant: ABBOTT LABORATORIES
Inventor： LEE, Chih-Hung , PERNER, Richard, J. , LARSON, Daniel, P. , KOENIG, John, R. , GOMTSYAN, Arthur, R. , ZHENG, Guo Zhu , DIDOMENICO, Stanley , STEWART, Andrew, O. , BAYBURT, Erol, K.
IPC: C07C233/74 , A61K31/166 , A61K31/18 , A61P21/00
CPC classification number: C07D213/40 , C07D213/68 , C07D213/71 , C07D239/34 , C07D309/12 , C07D317/72 , C07D333/20 , C07D333/34 , C07D333/72
Abstract: Compounds of formula (I), are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.
Abstract translation: 式（I）化合物是新型P2X3和P2X2 / P2X3拮抗剂，其可用于治疗疼痛，尿失禁和膀胱过度活动。
-
35.发明公开TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS 有权三取代-N - （（1S）-1,2,3,4-四氢-1-萘基）苯甲酰胺WHAT P2X3和P2X2 / 3 CONTAINING受体INHIBIT
公开(公告)号：EP1392643A2
公开(公告)日：2004-03-03
申请号：EP02739257.0
申请日：2002-05-14
Applicant: Abbott Laboratories
Inventor： LEE, Chih-Hung , PERNER, Richard, J. , LARSON, Daniel, P. , KOENIG, John, R. , GOMTSYAN, Arthur, R. , ZHENG, Guo Zhu , DIDOMENICO, Stanley , STEWART, Andrew, O. , BAYBURT, Erol, K.
IPC: C07C233/74 , A61K31/166 , A61K31/18 , A61P21/00
CPC classification number: C07D213/40 , C07D213/68 , C07D213/71 , C07D239/34 , C07D309/12 , C07D317/72 , C07D333/20 , C07D333/34 , C07D333/72
Abstract: Compounds of formula (I), are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.
-
Patent Agency Ranking36.发明授权BENZISOTHIAZOLE-1, 1-DIOXIDE ACTING AS ANTAGONISTS TO THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF 有权作为拮抗剂AGAINST香草素亚型1（VR1）代理苯并异噻唑-1,1-二氧化物及其应用
公开(公告)号：EP1836200B1
公开(公告)日：2012-05-16
申请号：EP05853514.7
申请日：2005-12-07
Applicant: Abbott Laboratories
Inventor： BROWN, Brian, S. , KEDDY, Ryan, G. , LEE, Chih-Hung
IPC: C07D417/04 , A61K31/425
CPC classification number: C07D451/02 , C07D275/06 , C07D417/04
Abstract: Compounds having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein L, A, G, R1, R2 and R3 are as defined herein. These compounds are particularly useful in the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder overactivity and urinary incontinence.
-
37.发明公开AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF 有权酰胺衍生物为阳性变构调节剂及其使用方法
公开(公告)号：EP2250162A2
公开(公告)日：2010-11-17
申请号：EP09707625.1
申请日：2009-02-06
Applicant: Abbott Laboratories
Inventor： MORTELL, Kathleen H. , NERSESIAN, Diana L. , SCHRIMPF, Michael R. , LEE, Chih-Hung , GOPALAKRISHNAN, Murali
IPC: C07D401/12
CPC classification number: C07D401/12 , C07D209/08 , C07D403/12 , C07D471/04
Abstract: The invention relates to novel amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.
-
38.发明公开
公开(公告)号：EP2012778A2
公开(公告)日：2009-01-14
申请号：EP07760554.1
申请日：2007-04-12
Applicant: Abbott Laboratories
Inventor： BROWN, Brian S. , KOENIG, John R. , GOMTSYAN, Arthur R. , LEE, Chih-Hung
IPC: A61K31/416 , A61K31/352 , C07D231/56 , C07D493/00
CPC classification number: C07D491/107 , C07D405/12 , C07D493/10
Abstract: The present invention is directed to compounds of formula (I), wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.
-
39.发明公开FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR 有权CONDENSED AZABICYCLISCHEVERBINDUNGEN作为香草素受体1的抑制剂（VR1）
公开(公告)号：EP1478363A1
公开(公告)日：2004-11-24
申请号：EP03716014.0
申请日：2003-02-11
Applicant: Abbott Laboratories
Inventor： LEE, Chih-Hung , BAYBURT, Erol, K. , DIDOMENICO, Stanley Jr. , DRIZIN, Irene , GOMTSYAN, Arthur, R. , KOENIG, John R. , PERNER, Richard, J. , SCHMIDT, Robert G. , TURNER, Sean C. , WHITE, Tammie, K. , ZHENG, Guo, Zhu
IPC: A61K31/502 , C07D217/02 , C07D237/28 , C07D217/22 , C07D209/08 , C07D231/56 , A61K31/472 , A61K31/416 , A61K31/404
CPC classification number: C07D249/08 , A61K31/404 , A61K31/416 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D209/08 , C07D217/02 , C07D217/22 , C07D217/24 , C07D217/26 , C07D231/12 , C07D231/56 , C07D233/56 , C07D237/28 , C07D401/12 , C07D405/12
Abstract: Compounds of formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
-
40.发明公开5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS 失效5,7- DISUBSTITIERTE 4-AMINOPYRIDO¬2,3-D嘧啶类化合物及其作为腺苷激酶抑制剂的
公开(公告)号：EP0989986A1
公开(公告)日：2000-04-05
申请号：EP98918093.0
申请日：1998-04-14
Applicant: Abbott Laboratories
Inventor： BHAGWAT, Shripad, S. , LEE, Chih-Hung , COWART, Marlon, D. , MCKIE, Jeffrey , GRILLOT, Anne, Laure
IPC: C07D471/04 , A61K31/495
CPC classification number: A61K31/5377 , A61K31/519 , C07D471/04
Abstract: A method for inhibiting adenosine kinase by administering a compound having formula (I) wherein R?1 and R2¿ are independently selected from H, loweralkyl, C¿1?-C6alkoxyC1-C6alkyl, arylC1-C6alkyl, -C(O)C1-C6alkyl, -C(O)aryl, -C(O)heterocyclic or may join together with the nitrogen to which they are attached to form a 5-7 membered ring optionally containing 1-2 additional heteroatoms selected from O, N or S; R?3¿ is selected from the group consisting of loweralkyl, loweralkenyl, loweralkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic group, heteroarylalkyl or heterocycloalkyl wherein the heteroaryl and heterocyclic groups are linked directly or indirectly by a ring carbon; R4 is selected from the group consisting of loweralkyl, loweralkenyl, loweralkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic group heteroarylalkyl or heterocycloalkyl; and a dashed line --- indicates that a double bond is optionally present provided that proper valencies are maintained, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R?1, R2, R3 and R4¿ are separately defined.
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.036 seconds)
